Health Canada authorizes P-I clinical trial of Mod...
August 10, 2026
Takeaways: This approval strengthens Lilly’s competitive stance against other GLP-1/GIP agents in the obesity space by adding a disease-specific indication (OSA) that ties directl...
Takeaways: Exdensur positions GSK as the first biologic in Canada with twice-yearly dosing for severe eosinophilic asthma, a major convenience advantage over existing IL‑4/5...
Takeaways: Heidi’s native Accuro EMR integration gives it instant scale across Canada’s largest clinician EMR (25,000+ users), making it more sticky and defensible while enab...
Takeaways: Shortening Breyanzi’s required stay-near-centre period and driving ban lowers the logistical and financial barriers to CAR T, which should modestly expand the eligible treat...
Real world evidence (RWE) is rapidly reshaping how therapies are evaluated, approved, and commercialized within global healthcare systems, including Canadian Health. Derived from real world data such ...
Takeaways: Kye Pharmaceuticals’ launch of Dyanavel XR in Canada adds a first-and-only chewable/swallowable extended-release amphetamine for ADHD in adults and children 6–12 years, alig...
Takeaways: Roche’s dual-formulation (IV and SC) authorization for Lunsumio (mosunetuzumab) in Canada creates flexible, fixed-duration access for relapsed/refractory follicular lymphoma...
Takeaways: Novo Nordisk’s updated Rybelsus in Canada is a smaller-tablet, lower-milligram GLP-1 formulation that delivers the same clinical effect as the original 3/7/14 mg doses, with 1.5/4/9 m...
Takeaways: The pCPA Letter of Intent for PrOKEDI (risperidone LAI) moves Bausch Health toward public reimbursement and broader access for Canada’s schizophrenia population, w...
Takeaways: The positive recommendation from CDA-AMC, backed by Phase III BE HEARD I and II trials, should accelerate payer negotiations and improve access for patients with chronic, pa...
